- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03264079
Effect of Itraconazole on the Pharmacokinetics of Bardoxolone Methyl in Healthy Adults
An Open-Label Study of the Effect of a Strong CYP3A4 Inhibitor (Itraconazole) on the Pharmacokinetics of Bardoxolone Methyl in Healthy Volunteers
This trial will study the impact of a strong CYP3A4 inhibitor (itraconazole) on the pharmacokinetics of bardoxolone methyl (RTA 402) in healthy adult subjects.
This is an open-label, fixed-sequence crossover pharmacokinetic (PK) study in healthy volunteers.
Subjects will complete a screening visit within 28 days of Study Day 1. Subjects must qualify for the study based on inclusion/exclusion criteria. For Period 1, all qualified subjects shall receive a single oral dose of bardoxolone methyl (10 mg) on Day 1. For Period 2, following a washout of 14 days, itraconazole (SPORANOX®) capsules (100 mg) will be administered as a 200-mg single daily dose on Study Days 15 through 27, with bardoxolone methyl (10 mg) administered on Day 18 (1 hour after itraconazole administration).
Bardoxolone methyl doses will be administered under fasted conditions. Itraconazole will be administered under fed conditions on Study Days 15-17, and Study Days 19-27.
On study Day 18, itraconazole will be administered under fasted conditions. Subjects will be confined beginning on Study Day -1 through the last blood sample collection on Study Day 9 during Period 1, and from Study Day 14 through the last PK blood draw on Study Day 28 during Period 2.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45227
- Medpace Clinical Pharmacology Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female and age is between 18 and 55 years, inclusive;
- Female subjects of childbearing potential must not be planning a pregnancy, pregnant, or lactating, and must have a negative serum pregnancy test result before enrollment into the study, and must be willing to use contraception as specified or abstain from sexual activity for the duration of the study;
- If male, subject must be surgically sterile or practicing an approved method of contraception, from initial study drug administration through 90 days after administration of the last dose of study drug;
- If male, subject agrees to abstain from sperm donation through 90 days after administration of the last dose of study drug;
- Body Mass Index (BMI) is ≥ 18 to ≤31 kg/m2, inclusive;
- A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG), as judged by the investigator;
- Must voluntarily sign and date each informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.
Exclusion Criteria:
- History of clinically significant drug allergies, including allergies to any of the components of the investigational product and/or clinically significant food allergies as determined by the investigator;
- Presence or history of any significant cardiovascular, gastrointestinal, hepatic, renal, pulmonary, hematologic, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease, as determined by the investigator;
- Presence of any other condition (including surgery) known to interfere with the absorption, distribution, metabolism, or excretion of medicines;
- Known hypersensitivity to any component in the formulations of bardoxolone methyl, or SPORANOX®;
- Requirement for any over-the-counter and/or prescription medication, vitamins, and/or herbal supplements on a regular basis;
- Use of any medications (over-the-counter and/or prescription medication), vitamins, and/or herbal supplements, within the 30-day period prior to study drug administration or within 5 half-lives (if known), whichever is longer;
- Recent (6-month) history of drug or alcohol abuse;
- B-type natriuretic peptide (BNP) level >200 pg/mL at screening;
- Positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or HIV antibodies (HIV Ab) at screening;
- Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration;
- Receipt of any investigational product within a time period equal to 10 half-lives of the product, if known, or a minimum of 30 days prior to study drug administration;
- Positive screen results for drugs of abuse, alcohol, or cotinine at screening or Day -1;
- Consumption of alcohol within 72 hours prior to study drug administration;
- Consumption of grapefruit, grapefruit products, star fruit, star fruit products, or Seville oranges within the 72-hour period prior to study drug administration;
- Use of tobacco or nicotine-containing products within the 6-month period preceding study drug administration;
- Current enrollment in another clinical study;
Screening laboratory analyses that show any of the following abnormal laboratory results:
- Alanine transaminase (ALT) or aspartate aminotransferase (AST) levels above the upper limit of normal (ULN);
- Clinically significant abnormal ECG; ECG with QTc using Fridericia's correction formula (QTcF) > 450 msec is exclusionary;
- Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive either bardoxolone methyl or itraconazole.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bardoxolone methyl 10 mg and Itraconazole 200 mg
Period 1: Bardoxolone methyl capsules 10 mg Period 2: two Itraconazole capsules 100 mg
|
One 10 mg capsule of bardoxolone methyl administered on Study Day 1 (Period 1) of the trial and one 10 mg capsule of bardoxolone methyl administered on Study Day 18 (Period 2) of the trial
Other Names:
Two 100 mg capsules of itraconazole administered once daily during Study Days 15 - 27 (Period 2) of the trial
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the plasma concentration-time curve of bardoxolone methyl from time 0 to the last measurable time point (AUC0-t).
Time Frame: 28 days
|
28 days
|
Area under the plasma concentration-time curve of bardoxolone methyl extrapolated to infinity (AUC0-inf)
Time Frame: 28 days
|
28 days
|
Maximum observed drug concentration (Cmax) in plasma of bardoxolone methyl
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Itraconazole
Other Study ID Numbers
- 402-C-1701
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hangzhou Sciwind Biosciences Co., Ltd.RecruitingHealthy VolunteersChina
Clinical Trials on Bardoxolone methyl capsules 10 mg
-
Reata, a wholly owned subsidiary of BiogenTerminatedConnective Tissue Disease-Associated Pulmonary Arterial HypertensionUnited States, Spain, Japan, Australia, United Kingdom, Canada, Germany, Belgium, Argentina, Israel, Mexico, Brazil, Czechia, Netherlands, Philippines
-
Reata, a wholly owned subsidiary of BiogenCompletedIdiopathic Pulmonary Fibrosis | Pulmonary Arterial Hypertension | Pulmonary Hypertension | Interstitial Lung Disease | Sarcoidosis | Idiopathic Interstitial Pneumonia | Cryptogenic Organizing Pneumonia | Desquamative Interstitial Pneumonia | Respiratory Bronchiolitis Associated Interstitial Lung Disease and other conditionsUnited States, Germany
-
Reata, a wholly owned subsidiary of BiogenWithdrawn
-
BiogenTerminatedType 2 Diabetes | Chronic Kidney Disease
-
Reata, a wholly owned subsidiary of BiogenCompletedFocal Segmental Glomerulosclerosis | IgA Nephropathy | Autosomal Dominant Polycystic Kidney | CKD Associated With Type 1 DiabetesUnited States
-
Reata, a wholly owned subsidiary of BiogenTerminatedDiabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Reata, a wholly owned subsidiary of BiogenWithdrawnDiabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
-
Reata, a wholly owned subsidiary of BiogenCompletedHealthy | Hepatic ImpairmentUnited States